Merus

Businessman climbing steps to pluck a star from the sky
Biotech

Merus hails 'unprecedented' survival on solid tumor bispecific

Merus reported a 79% 12-month survival rate, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.”
Nick Paul Taylor May 23, 2025 7:35am
An arrow incrementally going up stairs before pointing straight up Blue background

Merus touts cancer drug's strong profile with new data drop

Dec 2, 2024 11:59am
delay

FDA delays decision on Merus' first-in-class cancer drug

Nov 5, 2024 9:14am
target reach ladder climb meet win beat competition

Merus cancer bispecific lives up to investors' expectations

May 24, 2024 8:53am
Graphic of two hands shaking under a red and purple light

Gilead bets $1.5B-plus on Merus' trispecifc T-cell engagers

Mar 6, 2024 10:02am
down bankruptcy end arrow

Merus shares dip as lung cancer data reveal 3 patient deaths

Dec 4, 2023 1:04pm